| 4.47 -0.25 (-5.3%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.94 |
1-year : | 9.63 |
| Resists | First : | 6.8 |
Second : | 8.25 |
| Pivot price | 6.13 |
|||
| Supports | First : | 4.46 |
Second : | 3.71 |
| MAs | MA(5) : | 4.77 |
MA(20) : | 6.35 |
| MA(100) : | 5.16 |
MA(250) : | 8.36 |
|
| MACD | MACD : | -0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 2.8 |
D(3) : | 2.6 |
| RSI | RSI(14): 30.5 |
|||
| 52-week | High : | 41.79 | Low : | 3.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ QNRX ] has closed above bottom band by 7.9%. Bollinger Bands are 134.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.82 - 4.85 | 4.85 - 4.87 |
| Low: | 4.39 - 4.43 | 4.43 - 4.46 |
| Close: | 4.42 - 4.47 | 4.47 - 4.51 |
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Mon, 28 Sep 2026
Weekly Recap: Interim Phase 2/3 QRX003 success and Lake Street $20.00 target - TradingView
Thu, 24 Sep 2026
Quoin Pharmaceuticals Ltd. (QNRX) Posts Positive Interim QRX003 Data, Announces Up To $50M Financing - TradingView
Tue, 22 Sep 2026
Shareholders in Quoin (QNRX) face vote on letting warrant holders own more and gain extra voting power - Stock Titan
Tue, 22 Sep 2026
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome - Yahoo! Finance Canada
Tue, 22 Sep 2026
A rare skin disease has no approved treatment. Quoin’s treatment candidate got FDA Fast Track. - Stock Titan
Thu, 10 Sep 2026
Quoin (NASDAQ: QNRX) closes a private deal that could bring in tens of millions - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 66.3 (%) |
| Shares Short | 111 (K) |
| Shares Short P.Month | 156 (K) |
| EPS | -5.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -114.6 % |
| Return on Equity (ttm) | -575.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.79 |
| PEG Ratio | 0 |
| Price to Book value | 0.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|